Fidelity SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Bio-Matrix Scientific Group Inc. (BMSN)

BMSN RSS Feed
Add BMSN Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator solidgold, vegasdrummer, stockchaser64, The PoPo, Meach2, d5wr59mfi8
Search This Board:
Last Post: 12/19/2014 8:38:29 AM - Followers: 1093 - Board type: Free - Posts Today: 4
 


 


(Majority-Owned Susidiary of BMSN)
 
Regen BioPharma, Inc., a subsidiary of Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN)
is a biotechnology company focused on identifying undervalued regenerative medicine applications
in the stem cell space and rapidly advancing these technologies through pre-clinical andPhase I/ II clinical trials.
 

Stem Cell Medicine

 

"Our business model is to acquire and form companies around
undervalued assets identified froma highly focused analysis of issued
patents in regenerative medicinethat have demonstrated proof of 
concept"


 

Dr. Ichim is one of the leading authorities in the
world on stem cell bi
ology.

"A STEM CELL INCUBATOR COMPANY"

With an emphasis on stem cell regenerative medicine

 


 

Our Business Model | Regen BioPharma
                            

our business model 

Regen BioPharma has assessed over 20,000 stem cell related issued patents, narrowed down to 2000 patents with commercial applicability, and further identified 30 patents available for licensing. The company seeks to inlicense, take the product to, and through clinical safety and efficacy "signal" and spin out technologies.

 



 

Our Approach | Regen BioPharma

 

           

      REGEN BIOPHARMA AVOIDS WASTE OF "ONE PRODUCT/ONE INFRASTRUCTURE" APPROACH

      In the "Conventional Model", stem cell companies are started with one basic technology, infrastructure is developed around that                       technology, then if the technology fails, significant resources are lost that have been used in the product-specific development
 

             Conventional Model
conventional model

             Regen BioPharma Model
regen model


 



Operational Plan
 

Month 1-2: Assembly of Team:
Regen intends to assemble a team of world-class leaders in the spheres of Technology, Intellectual Property assessment, valuation and Clinical development. Regen will seek to compile a team of Physician-Scientists with experience in the area of clinical trials for regenerative medicine/stem cell products, Regulatory experts who have successfully taken products through the FDA and corresponding agencies internationally, and Biotech Entrepreneurs who have track records of excellence in business formation and value optimization. -DONE
 
Month 1-4: Inlicensing of Intellectual Property:
The Company having already assessed over 20,000 issued patents and havingcompiled a shortlist of 30 targets; Regen will seek to execute licensing deals on an initial core of 3 technologies. Regen focuses onissued patents that have already passed preclinical studies but are not under clinical development. -DONE
 
Month 3-6: Interaction with Regulatory Agencies:
Regen intends to develop data packages for each of the technologies andinitiate interaction with Regulatory Agencies such as the FDA for initiation of trials.-DONE
 
Month 6-18: Clinical Implementation:
Regen intends to launch clinical trials with world-leading institutions to obtain human safety data and "signal" of therapeutic efficacy.  NEXT UP
 
Month 18-24: Exit:
It is intended that technologies "incubated" by Regen will be spun off either as separate companies, or sold to Large Pharma companies seeking to enhance their therapeutic pipeline.
 
 

 



"At present there exists a wealth of intellectual property that is 'collecting dust' in the corridors of Academia. Given the field of regenerative medicine and stem cell therapy is so young, and the business models are fuzzy at best in terms of valuation, we see this space as a unique opportunity for acceleration of clinical development/value optimization," said Bio-Matrix Chairman & CEO David Koos about its Regen BioPharma. "Valuations for stem cell companies that have passed the threshold of clinical safety, with signals of efficacy are astronomical. The $1.8 billion Mesoblast-Cephalon deal, as well as recent financings of private companies with as little as 3 patient data such as Promethera ($31 million) or Allocure with 16 patients ($23 million), is testimony to the extremely high valuations that are characteristic of this space."

 

 





Regen BioPharma Pipeline

 
HemaXellerate I™ FDA FILING
[Regen BioPharma filed an Investigational New Drug (IND) Application on February 5th, 2013.  Regen BioPharma has received approval from the FDA for the clinical protocol and the product manufacturing information for HemaXellerate I.  On May 9, 2014 Regen BioPharma submitted clarification on animal safety studies that the FDA requested with review anticipated within 30 days.]

HemaXellerate I is a cellular therapy designed to heal damaged bone marrow. HemaXellarate I utilizes a collection of cells harvested from the patient’s own adipose (fat) tissue to repair damaged bone marrow and stimulate production of blood cells . The initial application of HemaXellerate I will be the treatment of severe aplastic anemia, a rare and serious condition in which the bone marrow fails to make enough blood cells: red blood cells, white blood cells, and platelets. In practice, the physician is shipped a kit, which is used to collect adipose tissue. The tissue is sent to a processing facility, and a standardized cellular product is delivered in a ready-to-use manner for administration into the patient intravenously.

**The Company intends to seek Orphan Drug Designation under the Orphan Drug Act of 1983 from the US Food and Drug Administration for HemaXellerate I**

 
dCellVax™
[Regen BioPharma is currently in the preclinical stage of development for dCellVax and plans to file an Investigational New Drug Application in August 2014]

The dCellVax therapeutic product is based on extracting blood from patients, growing a specialized type of immune cell from the blood called the "dendritic cell" and then subsequently genetically modifying the dendritic cell to become resistant to cancer's immune suppressive activity. It is known that cancer modifies the immune system by producing proteins which result in immune suppression. One such protein which cancer stimulates is an enzyme, indolamine 2,3 deoxygenase (IDO), which cancer turns on in dendritic cells. While dendritic cells are usually immune stimulators, dendritic cells found in cancer patients suppress the immune system as a result of expressing IDO.

The dCellVax therapeutic product uses patents that Regen BioPharma has in-licensed from Dr. Wei-Ping Min coupled with patents in-licensed from Benitec BioPharma.  By utilizing methods covered in both of these patents Regen BioPharma hopes to develop an immune-based, non-toxic cancer treatment initially targeting breast cancer.

HemaXellerate II™
[Regen BioPharma is currently in the preclinical stage of development for HemaXellerate II]

HemaXellerate II is intended to be a universal donor endothelial cell based therapeutic and is intended to be manufactured by obtaining cells from a part of the placenta called the “vascular lobules”. The cells are processed and utilized for the purpose of stimulating bone marrow hematopoetic stem cell repair and proliferation. The mechanism of action for HemaXellerate II is similar to HemaXellerate I whereby the harvested and processed cells would produce growth factors which would mediate the therapeutic effects of the product.

 



Managent Team | Regen BioPharma
 


David R. Koos, PhD, DBA

Chairman and Chief Executive Officer

David Koos is the Founder, Chairman & CEO of Entest BioMedical Inc. Dr. Koos has over 26 years of investment banking and venture capital experience with a primary focus on fully reporting medical and biotechnology ventures. He holds a Ph.D. degree in Sociology and a Doctor of Business Administration in Finance. Additionally, he has authored or co-authored several peer reviewed journal articles primarily on biotechnology related subjects.




Thomas E. Ichim, PhD

Chief Scientific Officer and Board Member

Dr. Ichim is a seasoned biotechnology entrepreneur with a track record of scientific excellence. He has founded/co-founded several companies including Medvax Pharma Corp, ToleroTech Inc, bioRASI, and OncoMune LLC. Dr. Ichim is a member of Vendevia Group, an innovative venture development organization focused on optimization of value in biotechnology ventures. He is scientific advisor to Orcrist Bio, Entest, and MBVaX. To date he has published 91 peer-reviewed articles and is co-editor of the textbook “RNA Interference: From Bench to Clinical Translation”. Ichim is an ad-hoc editor and sits on several editorial boards. Ichim is inventor on over 30 patents and patent applications. CV

 



Advisory Board | Regen BioPharma

 


Weiping Min, M.D.

Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.



David James Graham White, M.D., Ph.D.

Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University.

David A. Suhy, PhD

Dr Suhy has a long-term interest in development of shRNA based therapeutics to treat human diseases. He is in the unique position of seeing of directing the research of a RNAi-based therapeutic from its earliest inception until it reaches clinical trials. Development of a shRNA therapeutic against the Hepatitis C virus (HCV) was initiated at Avocel in 2003. Financial constraints caused the company to shutter research operations in 2006.Upon raising venture capital, Tacere Therapeutics acquired the rights to the HCV family of drugs and brought back Dr. Suhy to head the program. Partnered with Pfizer shortly thereafter, this drug is their first foray into gene therapy-based approaches and is the first shRNA program partnered with a large pharma. Given Pfizer’s lack of experience in both areas, Dr. Suhy has played a pivotal role in its development as Tacere has continued to lead the research efforts for advancement of this product into the clinic and has stood side-by-side with Pfizer through all of the regulatory agency meetings.

 


 

Current Business Partners | Regen BioPharma

 
                                                                
                                         
   

 


 


 

                        News and Recent Press Releases:
 

05/12/2014 12:30 Regen Biopharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND...
03/06/2014 14:53 Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Subsidiary, Regen BioPharma, Inc.
12/11/2013 09:35 Regen BioPharma Announces HemaXellerate I (TM) Efficacy Data in Animal Model of Aplastic Anemia

10/31/2013 11:35 Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I
10/09/2013 15:11 Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders
09/26/2013 08:00 Bio-Matrix Scientific Group's Subisidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I..
09/25/2013 08:30 Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product
09/17/2013 10:06 Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board
08/16/2013 13:47 Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program
08/08/2013 09:47 Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma
07/31/2013 14:36 Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I (TM) Clinical Program
06/07/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
05/06/2013 08:30 Bio-Matrix Scientific Group's Regen BioPharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
04/04/2013 16:09 Bio-Matrix Scientific Group's Regen BioPharma Provides Update on Preclinical and Clinical Development
03/18/2013 09:57 Regen BioPharma Receives IND # From FDA for HemaXellerate
02/26/2013 10:12 Bio-Matrix Scientific Group's Regen BioPharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing...
02/05/2013 10:35 Regen BioPharma Files Investigational New Drug (IND) Application With FDA on HemaXellerate I (TM) Stem Cell Drug For Aplastic...
01/24/2013 14:53 Regen BioPharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate (TM) Bone Marrow Failure Product




  





















 



 


 
 
 
(Majority-Owned Susidiary of BMSN)

Overview

Entest BioMedical Inc.(OTCQB: ENTB) develops immuno-therapeutic treatments that address illnesses and maladies in both veterinary and human medicine.  Of specific interest to us are immunological vaccines for oncology (cancer vaccines) and veterinary clinic acquisitions.  The basis for the majority of our approaches is underpinned by leveraging the body's own reparative / immunological mechanisms - as opposed to using toxic chemicals.

Areas of Focus
 
Currently, Entest is focused on significant therapeutic therapies that show promise for the development of under-served market niches with potential high demand.

 
 

 


Bio-Matrix Scientific Group's Stock Information 

OS 3,079,910,118  (OS accurate as of 09/24/14)
 
Authorized Shares: 5,000,000,000

 

BMSN Transfer Agent:
Securities Transfer Corporation

2591 Dallas Parkway Suite 102

Frisco, Texas 75034

Phone - 469-633-0101

FAX 469-633-0088

 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
BMSN
Current Price
Volume:
Bid Ask Day's Range
Wiki
BMSN News: Current Report Filing (8-k) 11/07/2014 05:20:02 PM
BMSN News: Current Report Filing (8-k) 09/19/2014 08:51:33 AM
BMSN News: Quarterly Report (10-q) 08/13/2014 03:58:15 PM
PostSubject
#146964  Sticky Note Press play: http://www.hematology.org/Annual-Meeting/2361.aspx Mods please sti Greedy G 12/09/14 09:17:26 AM
#145968  Sticky Note FDA ISSUES IND NUMBER FOR REGEN BIOPHARMA'S dCellVax d5wr59mfi8 11/08/14 01:25:39 AM
#145781  Sticky Note RGBP NEWS: Meach2 11/04/14 08:46:18 PM
#143541  Sticky Note SUMMARY OF HEMAXELLERATE I PROGRESS (UPDATED SEPT 2014): GM_FSJ 09/14/14 01:11:29 PM
#134995  Sticky Note Please stay on topic. The only topic to IH Admin [Dan] 06/03/14 05:06:37 PM
#147331   Merry Christmas inventor1. ADVFN_franknstein 12/19/14 08:38:29 AM
#147330   You may be surprised, but i think YOU angelicsatan666 12/19/14 07:32:07 AM
#147329   Same here INVENTOR 1 MERRY CHRISTMAS ohmyohmy 12/19/14 07:09:54 AM
#147328   You may be very surprised when all is inventor1 12/19/14 01:30:08 AM
#147327   http://www.regenbiopharma.com/news-events.html MakeittoV221 12/18/14 05:48:16 PM
#147326   And the "KOOS and CRONIES SYNDICATE" hopeful March angelicsatan666 12/18/14 05:44:59 PM
#147325   Look at the chart every March Abomb1357 12/18/14 05:23:03 PM
#147324   BMSN consolidation still in progress. No worries. Greedy G 12/18/14 04:16:02 PM
#147322   Bid keeps building! Oooooo yes! Greedy G 12/18/14 03:28:17 PM
#147321   Any body NOT selling here is very stupid!!!!!..........:) PARker1703 12/18/14 03:23:05 PM
#147320   I sure hope no one bought tons of Fred Fry 12/18/14 03:22:27 PM
#147319   I got out with a few million ohmyohmy 12/18/14 03:08:10 PM
#147318   Anybody selling here is either crazy or just Natureboy1 12/18/14 02:22:16 PM
#147317   Here is one example of BMSN seeking less Greedy G 12/18/14 02:00:42 PM
#147316   Nooooooope!! This GRAVEY TRAIN WELFARE ATM will continue UNTIL angelicsatan666 12/18/14 01:40:55 PM
#147315   Yes that's what I got from the 10K Greedy G 12/18/14 01:37:51 PM
#147314   100k was bought by a private investor to GM_FSJ 12/18/14 01:37:24 PM
#147313   think we are done paying debtors with BMSN stock? fuzzyforeigner 12/18/14 01:24:27 PM
#147312   Bid building 8M > 9M Little run up before Greedy G 12/18/14 12:23:12 PM
#147311   ~ BMSN = Nice = "Pieces of .0008"+.0001(+14.29%)!! ;-) 1-eye-jack 12/18/14 12:04:21 PM
#147310   You are correct sir 'patience' is key! I think Greedy G 12/18/14 11:57:39 AM
#147309   Been asked many times by friends how I marchon 12/18/14 11:38:03 AM
#147308   There is rich and then there is super marchon 12/18/14 11:33:17 AM
#147307   I know it's hard to keep reading this, marchon 12/18/14 11:13:36 AM
#147306   This is Great the company files properly when Greedy G 12/18/14 09:36:30 AM
#147305   Doesn't matter what kind of news they come herbster 12/18/14 08:59:29 AM
#147304   RGBP 8K out! BMSN owns 58% of Greedy G 12/18/14 08:41:03 AM
#147303   A WHOLE LOT of NOTHING!- HAHAHAHAHAHAHAH RGBP will, as angelicsatan666 12/18/14 07:38:24 AM
#147302   News out RGBP BobbyR 12/18/14 07:08:39 AM
#147301   Just stay tuned. Rome and Paris haven't been sante1 12/17/14 10:07:31 PM
#147300   Merry Christmas and Happy New Year Beek! I jayreese 12/17/14 07:35:40 PM
#147299   This DEADWEIGHT by the "KOOS and CRONIES SYNDICATE" angelicsatan666 12/17/14 06:25:20 PM
#147298   I'm going to give it a rest on the Beek 12/17/14 03:07:33 PM
#147297   Nothing happened yet.. That's why the pps is VvAngelvV 12/17/14 02:02:37 PM
#147296   My rule is hold everything until February -March Bapfitz 12/17/14 01:39:27 PM
#147295   Koos must be buying a new boat for PARker1703 12/17/14 12:58:15 PM
#147294   What ever happened to FDA approval for Hema ? eskimodobbs 12/17/14 12:56:19 PM
#147293   Yes yes. Saw that article aswell. Well, more VvAngelvV 12/17/14 12:40:14 PM
#147292   Look at bmsn"s chart... And then look at VvAngelvV 12/17/14 12:29:36 PM
#147291   I don't find any joy in the fact Fred Fry 12/17/14 12:13:52 PM
#147290   Well thats good that you diversify. I the Beek 12/17/14 11:35:48 AM
#147289   I'm in 5 plays now, it's only December, Greedy G 12/17/14 11:34:04 AM
#147288   Talked to me when it's at .0002 six the Beek 12/17/14 11:27:33 AM
#147287   Umm??? Seems some posters are good @ making Greedy G 12/17/14 11:15:49 AM
#147286   ouchhhhhhhhhhh...bad day in bedrock for BMSN....will see .0006 PARker1703 12/17/14 11:09:32 AM
#147285   Greedy get ready to be as bitter as the Beek 12/17/14 10:58:21 AM
#147284   Support holding really well :) Greedy G 12/17/14 10:34:22 AM
#147283   sorry to say jack.. .0005's coming soon !!!! truckerjoeh 12/17/14 10:32:51 AM
#147282   ~ BMSN = "Pieces of .0008's" Holding Gr88!! ;-) 1-eye-jack 12/17/14 10:26:28 AM
#147281   Institutions would never touch a pos like this Brakeman 12/17/14 10:20:58 AM
PostSubject